SCHEMBL181918

SCHEMBL181918

CC(C)OC(=O)CC(=O)C(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
TSHR P16473 4/20 0.42
MAPT P10636 2/20 0.36
CYP2D6 P10635 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
NLRP3 Q96P20 1/20 0.32
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29090137 0.98 LMNA (0.42) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL19864351 0.85 LMNA (0.37) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL229792 0.84 TSHR (0.50) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL28875912 0.81 LMNA (0.48) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL28727541 0.81 LMNA (0.48) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL18152012 0.81 LMNA (0.48) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL14095562 0.81 LMNA (0.41) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL7097260 0.81 LMNA (0.41) LMNATSHRMAPTCYP2D6ALDH1A1
SCHEMBL15437962 0.79 FAAH (0.39) LMNAMAPTEPHX2
SCHEMBL1012855 0.79 LMNA (0.46) LMNATSHRMAPTCYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167310-A1 CURING CATALYST AND RESIN COMPOSITION KOEI CHEMICAL COMPANY, LIMITED (JP) 2023-06-01 US claimed
EP-4144436-A1 CURING CATALYST AND RESIN COMPOSITION Koei Chemical Company, Limited (JP) 2023-03-08 EP claimed
CN-115461147-A Curing catalyst and resin composition 广荣化学株式会社 2022-12-09 CN claimed
US-12565595-B2 Aqueous coating material composition and method for forming multilayer coating film KANSAI PAINT CO., LTD. (JP) 2026-03-03 US disclosed
US-20250346779-A1 Method of Forming A Coating Film KANSAI PAINT CO LTD (JP) 2025-11-13 US disclosed
US-20250340751-A1 Automobile Body Coating Method KANSAI PAINT CO LTD (JP) 2025-11-06 US disclosed
US-20250154374-A1 AQUEOUS COATING MATERIAL COMPOSITION AND METHOD FOR FORMING MULTILAYER COATING FILM KANSAI PAINT CO., LTD. (JP) 2025-05-15 US disclosed
CN-113167961-B Method for manufacturing polarizing film, optical film, and image display device 日东电工株式会社 2025-02-28 CN disclosed
CN-116829662-B Aqueous coating composition and method for forming multilayer coating film 关西涂料株式会社 2024-10-29 CN disclosed
EP-3689476-B1 METHOD FOR FORMING MULTILAYER COATING FILM KANSAI PAINT CO LTD (JP) 2024-10-02 EP disclosed
US-20240309239-A1 AQUEOUS COATING MATERIAL COMPOSITION AND METHOD FOR FORMING MULTILAYER COATING FILM KANSAI PAINT CO., LTD. (JP) 2024-09-19 US disclosed
US-20090264654-A1 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2009-10-22 US disclosed
US-20090209693-A1 Silver Beta-Ketocarboxylate, Material Comprising the Same for Forming Silver Metal, and Use Thereof OSAKA INDUSTRIAL PROMOTION (JP) 2009-08-20 US disclosed
EP-2088142-A2 Compounds and Processes AstraZeneca UK Limited (GB) 2009-08-12 EP disclosed
US-7524955-B2 Process for the preparation of pyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2009-04-28 US disclosed
US-7524955-B2 Process for the preparation of pyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2009-04-28 US disclosed
EP-1905756-A1 SILVER BETA-KETOCARBOXYLATE, MATERIAL COMPRISING THE SAME FOR FORMING SILVER METAL, AND USE THEREOF OSAKA UNIVERSITY (JP) 2008-04-02 EP disclosed
US-20060052604-A1 Process for the Preparation of Pyrimidine Compounds ASTRAZENECA UK LIMITED (GB) 2006-03-09 US disclosed
EP-1578731-A2 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS AstraZeneca UK Limited (GB) 2005-09-28 EP disclosed
WO-2004054986-A2 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264654-A1 PROCESS FOR THE PREPARATION OF PYRIMIDINE COMPOUNDS DPYD, RIOX2, CCNE1 LMNA 2945/4885TSHR 1719/4885MAPT 4839/4885
US-12565595-B2 Aqueous coating material composition and method for forming multilayer coating film DRD2, CHRM1, PNMT LMNA 963/4885TSHR 3087/4885MAPT 609/4885
US-20090209693-A1 Silver Beta-Ketocarboxylate, Material Comprising the Same for Forming Silver Metal, and Use Thereof PCCA, BCKDK, MCCC2 LMNA 2691/4885TSHR 4710/4885MAPT 910/4885
US-20060052604-A1 Process for the Preparation of Pyrimidine Compounds DPYD, RIOX2, CCNE1 LMNA 3041/4885TSHR 1722/4885MAPT 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.